1,3-dipropyl-8-cyclopentylxanthine has been researched along with Parkinson Disease in 2 studies
DPCPX : An oxopurine that is 7H-xanthine substituted at positions 1 and 3 by propyl groups and at position 8 by a cyclohexyl group.
Parkinson Disease: A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The adenosine inhibition was abolished by 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), a selective adenosine A1 receptor antagonist." | 1.31 | Adenosine A1 receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat. ( Aceves, J; Barajas, C; Erlij, D; Florán, B; Florán, L, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mango, D | 1 |
| Bonito-Oliva, A | 1 |
| Ledonne, A | 1 |
| Cappellacci, L | 1 |
| Petrelli, R | 1 |
| Nisticò, R | 1 |
| Berretta, N | 1 |
| Fisone, G | 1 |
| Mercuri, NB | 1 |
| Florán, B | 1 |
| Barajas, C | 1 |
| Florán, L | 1 |
| Erlij, D | 1 |
| Aceves, J | 1 |
2 other studies available for 1,3-dipropyl-8-cyclopentylxanthine and Parkinson Disease
| Article | Year |
|---|---|
Adenosine A1 receptor stimulation reduces D1 receptor-mediated GABAergic transmission from striato-nigral terminals and attenuates l-DOPA-induced dyskinesia in dopamine-denervated mice.
Topics: Action Potentials; Age Factors; Animals; Antiparkinson Agents; Corpus Striatum; Disease Models, Anim | 2014 |
Adenosine A1 receptors control dopamine D1-dependent [(3)H]GABA release in slices of substantia nigra pars reticulata and motor behavior in the rat.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Adenosine; Animals; Calcium Signaling; Dopamine Agonists; Do | 2002 |